Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Nuvalent, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/04/2023 144 Form 144 - Report of proposed sale of securities:
10/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "SELECTED STATEMENTS OF OPERATIONS DATA 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 25,922 $ 13,558 $ 48,047 $ 26,251 General and administrative 8,140 5,175 16,225 10,170 Total operating expenses 34,062 18,733 64,272 36,421 Loss from operations Other income : Interest income and other income , net 4,972 267 9,990 406 Total other income, net 4,972 267 9,990 406 Net loss $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted average shares of common stock outstanding, basic and diluted 56,866,991 48,319,067 56,785,883 48,302,017 SELECTED BALANCE SHEET DATA June 30, December 31, 2023 2022 Cash, cash equivalents and marketable securities $ 431,239 $ 472,163 Working capital $ 416,197 $ 458,510 To..."
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/28/2023 144 Form 144 - Report of proposed sale of securities:
07/28/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 144 Form 144 - Report of proposed sale of securities:
06/16/2023 144 Form 144 - Report of proposed sale of securities:
06/16/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVALENT, INC. Nuvalent, Inc., a corporation organized and existing under the laws of the State of Delaware , hereby certifies as follows: 1. The name of the Corporation is Nuvalent, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was January 25, 2017 . 2. This Third Amended and Restated Certificate of Incorporation amends, restates and integrates the provisions of the Amended and Restated Certificate of Incorporation that was filed with the Secretary of State of the State of Delaware on April 30, 2021 , and was duly adopted in accordance with the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware . 3. The text..."
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "SELECTED STATEMENTS OF OPERATIONS DATA Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 22,125 $ 12,693 General and administrative 8,085 4,995 Total operating expenses 30,210 17,688 Loss from operations Other income : Interest income and other income, net 5,018 139 Total other income, net 5,018 139 Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted average shares of common stock outstanding, basic and diluted 56,703,873 48,284,778 SELECTED BALANCE SHEET DATA March 31, December 31, 2023 2022 Cash, cash equivalents and marketable securities $ 450,462 $ 472,163 Working capital $ 439,272 $ 458,510 Total assets $ 460,989 $ 482,459 Total liabilities $ 17,021 $ 19,481 Total stockholders’ equity $ 443,968 $ 46..."
05/05/2023 144 Form 144 - Report of proposed sale of securities:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/13/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "SELECTED STATEMENTS OF OPERATIONS DATA Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 22,855 $ 13,194 $ 63,731 $ 35,559 General and administrative 6,444 4,184 22,377 10,258 Total operating expenses 29,299 17,378 86,108 45,817 Loss from operations Other income : Change in fair value of preferred stock tranche rights — — — Interest income and other income, net 3,176 89 4,254 114 Total other income , net 3,176 89 4,254 Net loss $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted average shares of common stock outstanding, basic and diluted 53,616,336 48,268,256 49,668,864 21,783,754 SELECTED BALANCE SHEET DATA December 31, 2022 2021 Cash, cash equivalents and marketab..."
02/14/2023 SC 13G/A Fairmount Funds Management LLC reports a 5.5% stake in NUVALENT, INC.
02/10/2023 SC 13G/A Flynn James E reports a 39.2% stake in Nuvalent, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 15% stake in NUVALENT INC
11/14/2022 SC 13G/A Flynn James E reports a 39.2% stake in Nuvalent, Inc.
11/09/2022 SC 13G Fairmount Funds Management LLC reports a 5.1% stake in NUVALENT, INC.
11/03/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
10/31/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/28/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
08/17/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/17/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/10/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy